FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
H.C. Wainwright Starts FibroBiologics (FBLG) at Buy
October 30, 2024 7:55 AM EDTH.C. Wainwright analyst Matthew Caufield initiates coverage on FibroBiologics (NASDAQ: FBLG) with a Buy rating and a price target of $12.00.
The analyst comments "Fibroblast cellular therapieslooking first to diabetic foot ulcer indication as main focus. FibroBiologics, Inc. is a clinical stage biotechnology company focused on development of fibroblast cellular therapies for chronic diseases. The companys extensive US and... More
